ARXS · Arxis

The thesis

Arxis, a roll-up of defense, space and industrial component makers, is modestly more likely than not to beat the S&P 500 over the next three months. On 28 October 2026 it reported 29% organic growth and raised its 2026 outlook, and the shares have since moved back above their pre-report price. The fourth-quarter report, estimated for late February 2027, tests whether management holds the 10–15% organic growth it guides for 2027.

The last daily close was $53.79 on 12 November 2026. That is above the $51.74 close of 21 October 2026, the week before the report, and above the 50-day moving average of $50.99 on the same date. No Arxis press release or results filing has come out since the 29 October 2026 Form 10-Q.

The market still prices in a slowdown. Adjusted daily closes show the shares down 6.1% over three months to 12 November 2026 despite the raised outlook, so investors expect organic growth to fall from 29% toward the 10–15% guided for 2027. TransDigm, the largest listed aerospace component peer, guided on 10 November 2026 to fiscal 2027 net sales of $11.95–$12.15 billion, about 14% growth at the midpoint. That points to steady sector demand ahead of the Arxis report.

Bullish and bearish views on Arxis, Inc.

The bull case on Arxis, Inc. (ARXS), in brief: organic growth accelerated to 29%. The bear case: the 2027 outlook implies a slowdown.

Bull case

• Organic growth accelerated to 29%. The 28 October 2026 results release put third-quarter organic growth at 29%, up from 21% in the second quarter. Revenue was $564 million, up 36% year over year, with 7% from acquisitions. The 10-Q filed 29 October 2026 shows $563.98 million against $414.83 million a year earlier.
• The 2026 outlook rose again. On 28 October 2026 management lifted 2026 revenue guidance to $2.050–$2.070 billion from $1.960–$1.980 billion. Guidance for adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) rose to $855–$865 million from $790–$800 million.
• Third-quarter results beat estimates. Adjusted earnings per share of $0.37 beat a $0.29 estimate, and revenue beat a $540.2 million estimate, Benzinga reported on 28 October 2026.
• Cash flow and earnings stepped up. Third-quarter free cash flow was $150 million, up 117%. Net income under generally accepted accounting principles was $84 million, against a $10 million loss a year earlier, per the 28 October 2026 release.
• Debt fell during a busy deal year. The third-quarter 10-Q shows total debt of $1.719 billion at 30 September 2026, down from $2.633 billion at 31 December 2025, with cash of $493.7 million. The results release puts net leverage at 1.6 times at 30 September 2026, down from 1.8 times at 30 June 2026.
• The largest peer guided to steady growth. TransDigm's 10 November 2026 release guided fiscal 2027 net sales to $11.95–$12.15 billion and assumed growth in commercial original equipment, aftermarket and defense. A firm peer outlook supports sector valuations while Arxis has no event of its own before February.
• Analysts raised targets after the report. On 30 October 2026, Morgan Stanley raised its target to $66 from $62 (Overweight) and RBC Capital raised its target to $64 from $60 (Outperform), per Benzinga and fiscal.ai.

Bear case

• The 2027 outlook implies a slowdown. On 28 October 2026 Arxis guided to 10–15% organic growth in 2027, well below the 29% third-quarter rate. The shares closed at $50.82 on 30 October 2026 and did not close back above the $51.74 pre-report level until 11 November 2026.
• A director sold shares into weakness. A Form 4 filed 12 November 2026 shows director Kevin Scott Perhamus sold 25,000 shares in the open market on 9 November 2026, at $50.59–$51.19 (average $50.92). It is the only open-market insider sale in Arxis's recent SEC filings.
• Arxis must outgrow its biggest peer. TransDigm's fiscal 2027 guidance, released 10 November 2026, assumes defense revenue growth in the high single digits. Even the bottom of Arxis's 10–15% organic range sits above that.
• The third-quarter margin sits above guidance. The adjusted EBITDA margin was 45.4% in the third quarter. The 28 October 2026 release guides to about 41.7% for full-year 2026 and 42.1–42.4% for 2027, so later quarters are guided lower.
• Resale shares are already sellable. The S-1 filed 13 October 2026 registers resale of 13,351,964 Class A shares held by former Omnetics owners. It states that 4,422,677 were available for sale at filing, with the rest released in three equal tranches ending 15 May 2028.
• Acquisitions carry integration risk. Goodwill rose to $3.207 billion at 30 September 2026 from $2.745 billion at 31 December 2025, per the 10-Q. On 10 November 2026 TransDigm said recent acquisitions cut its own quarterly margin by about two percentage points, which shows how bought businesses can weigh on a roll-up's margins.

Price setup

The last daily close was $53.79 on 12 November 2026. That is above the 50-day moving average of $50.99 on the same date and above the $51.74 close of 21 October 2026, the last close before the third-quarter report. The October low was the $46.77 close on 8 October 2026. Adjusted daily closes show a 6.1% decline over three months to 12 November 2026.

The case turns on the $51.74 pre-report close. As long as the shares hold above it, the market is accepting the raised outlook despite the guided slowdown. Arxis priced its initial public offering at $28.00 on 15 April 2026, so it has too little trading history for a 200-day moving average. The supply visible in SEC filings is the 13,351,964-share resale registration and the director's 25,000-share sale on 9 November 2026. Those filings report no sale by Arcline, the sponsor.

Catalysts ahead

• ~25 February 2027 (est.): Arxis fourth-quarter 2026 results (the company has not yet announced the date). Shows whether 2026 revenue lands in the $2.050–$2.070 billion range and whether management holds the $2.400–$2.500 billion 2027 outlook and its 10–15% organic growth.

What would change the view

A daily close below $46.00, under the $46.77 close of 8 October 2026 that marked the October low, which would show the post-report recovery has failed. Organic growth below 10% in a reported quarter, or a cut to the $2.400–$2.500 billion 2027 revenue outlook, would also break the case.

The risks this note tracks, each with what would confirm it:

• Organic growth slows faster than the 10–15% guided for 2027. Confirmed by: a reported quarter with organic growth below 10%, or a cut to the $2.400–$2.500 billion 2027 revenue outlook.
• Sponsor, insider or resale selling adds supply and caps the price. Confirmed by: a registered secondary offering by Arcline, further open-market insider sales in Form 4 filings, or reported sales under the 13 October 2026 resale S-1.
• Continued acquisitions raise debt and dilute margins. Confirmed by: net leverage reported back above 1.8 times, or an adjusted EBITDA margin below the 42.1–42.4% guided for 2027.
• Sector demand cools and pulls aerospace component valuations lower. Confirmed by: a cut to TransDigm's fiscal 2027 sales guidance of $11.95–$12.15 billion at its next quarterly report.

What it trades with

Arxis trades with aerospace and defense component makers. TransDigm's 10 November 2026 outlook is the closest public comparison for both demand and valuation. Sponsor control, the resale registration and insider sales make share supply a factor specific to Arxis. The company went public on 15 April 2026, so its history of moving with the sector is short.